Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Marshall Wace LLP

Marshall Wace LLP lessened its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 98.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,624 shares of the company's stock after selling 977,280 shares during the quarter. Marshall Wace LLP's holdings in Syndax Pharmaceuticals were worth $167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. E Fund Management Co. Ltd. lifted its stake in shares of Syndax Pharmaceuticals by 14.4% in the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock valued at $167,000 after purchasing an additional 1,583 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Syndax Pharmaceuticals by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock worth $239,000 after buying an additional 1,732 shares during the last quarter. R Squared Ltd purchased a new position in Syndax Pharmaceuticals during the fourth quarter worth $26,000. Y Intercept Hong Kong Ltd raised its stake in shares of Syndax Pharmaceuticals by 2.5% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company's stock valued at $1,101,000 after acquiring an additional 1,995 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Syndax Pharmaceuticals by 1.2% in the fourth quarter. Bank of New York Mellon Corp now owns 224,261 shares of the company's stock valued at $2,965,000 after acquiring an additional 2,759 shares during the period.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock traded up $1.02 during trading on Thursday, reaching $11.01. 3,611,270 shares of the company were exchanged, compared to its average volume of 1,678,566. Syndax Pharmaceuticals, Inc. has a 52-week low of $9.66 and a 52-week high of $25.07. The company has a market capitalization of $947.34 million, a P/E ratio of -3.03 and a beta of 0.82. The stock's 50 day simple moving average is $12.65 and its two-hundred day simple moving average is $14.54.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.06. The company had revenue of $20.04 million for the quarter, compared to analysts' expectations of $15.88 million. The company's quarterly revenue was up 1900.0% compared to the same quarter last year. During the same period last year, the business earned ($0.85) EPS. As a group, equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Insider Transactions at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,777 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the transaction, the chief financial officer now directly owns 90,746 shares of the company's stock, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,683 shares of company stock worth $336,087 over the last ninety days. Company insiders own 4.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SNDX shares. Guggenheim reiterated a "buy" rating and set a $32.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday. HC Wainwright restated a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. JPMorgan Chase & Co. increased their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. Citigroup decreased their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $35.91.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).